Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sun Pharma | BSE | Healthcare | Pharmaceuticals | ₹4.26T | 38.5x | 1.3 | ₹1,775.20 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.6% Upside | Upgrade to Pro+ | |
Sun Pharma | NSE | Healthcare | Pharmaceuticals | ₹4.26T | 38.5x | 1.3 | ₹1,777.25 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.8% Upside | Upgrade to Pro+ | |
Divi's Labs | BSE | Healthcare | Pharmaceuticals | ₹1.57T | 85.3x | 2.2 | ₹5,896.15 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -4.5% Downside | Upgrade to Pro+ | |
Divi's Labs | NSE | Healthcare | Pharmaceuticals | ₹1.57T | 85.3x | 2.2 | ₹5,900.85 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -4.6% Downside | Upgrade to Pro+ | |
Cipla | NSE | Healthcare | Pharmaceuticals | ₹1.19T | 26.5x | 0.92 | ₹1,471.55 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.6% Upside | Upgrade to Pro+ | |
Cipla | BSE | Healthcare | Pharmaceuticals | ₹1.19T | 26.5x | 0.92 | ₹1,471.35 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.1% Upside | Upgrade to Pro+ | |
Torrent Pharma | NSE | Healthcare | Pharmaceuticals | ₹1.05T | 58.1x | 1.71 | ₹3,094.85 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17% Upside | Upgrade to Pro+ | |
Torrent Pharma | BSE | Healthcare | Pharmaceuticals | ₹1.05T | 58.1x | 1.71 | ₹3,094.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17% Upside | Upgrade to Pro+ | |
Mankind Pharma | BSE | Healthcare | Pharmaceuticals | ₹1.03T | 50.2x | 1.38 | ₹2,568 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.1% Upside | Upgrade to Pro+ | |
Mankind Pharma | NSE | Healthcare | Pharmaceuticals | ₹1.03T | 50.2x | 1.38 | ₹2,574.40 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.8% Upside | Upgrade to Pro+ | |
Dr Reddy’s Laboratories | BSE | Healthcare | Pharmaceuticals | ₹1.01T | 19x | 4.13 | ₹1,213.95 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.6% Upside | Upgrade to Pro+ | |
Dr Reddy’s Laboratories | NSE | Healthcare | Pharmaceuticals | ₹1.01T | 19x | 4.13 | ₹1,213.45 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.6% Upside | Upgrade to Pro+ | |
Zydus Lifesciences | BSE | Healthcare | Pharmaceuticals | ₹953.51B | 22.2x | 0.42 | ₹946.90 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.5% Upside | Upgrade to Pro+ | |
NSEI:ZYDUSLIFE | NSE | Healthcare | Pharmaceuticals | ₹953.51B | 22.2x | 0.42 | ₹947.60 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.4% Upside | Upgrade to Pro+ | |
Lupin | NSE | Healthcare | Pharmaceuticals | ₹929.82B | 35.4x | 0.36 | ₹2,038.20 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.8% Upside | Upgrade to Pro+ | |
Lupin | BSE | Healthcare | Pharmaceuticals | ₹929.82B | 35.4x | 0.36 | ₹2,037.05 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.4% Upside | Upgrade to Pro+ | |
Aurobindo Pharma | BSE | Healthcare | Pharmaceuticals | ₹726.06B | 20.4x | 0.37 | ₹1,247.90 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.2% Upside | Upgrade to Pro+ | |
Aurobindo Pharma | NSE | Healthcare | Pharmaceuticals | ₹726.06B | 20.4x | 0.37 | ₹1,250.10 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24% Upside | Upgrade to Pro+ | |
Alkem Laboratories Ltd BO | BSE | Healthcare | Pharmaceuticals | ₹661.17B | 31.1x | 0.65 | ₹5,525.25 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.3% Upside | Upgrade to Pro+ | |
Alkem Laboratories Ltd | NSE | Healthcare | Pharmaceuticals | ₹661.17B | 31.1x | 0.65 | ₹5,529.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.3% Upside | Upgrade to Pro+ | |
Abbott India | BSE | Healthcare | Pharmaceuticals | ₹578.50B | 45x | 2.41 | ₹27,193.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.3% Upside | Upgrade to Pro+ | |
Abbott India | NSE | Healthcare | Pharmaceuticals | ₹578.50B | 45x | 2.41 | ₹27,224.35 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.2% Upside | Upgrade to Pro+ | |
Glenmark Pharma | NSE | Healthcare | Pharmaceuticals | ₹421.21B | -48.1x | 0.05 | ₹1,492.65 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.6% Upside | Upgrade to Pro+ | |
Glenmark Pharma | BSE | Healthcare | Pharmaceuticals | ₹421.21B | -48.1x | 0.05 | ₹1,492.35 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.6% Upside | Upgrade to Pro+ | |
GlaxoSmithkline Pharma | NSE | Healthcare | Pharmaceuticals | ₹412.72B | 61.2x | 9.91 | ₹2,438 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.1% Upside | Upgrade to Pro+ | |
GlaxoSmithkline Pharma | BSE | Healthcare | Pharmaceuticals | ₹412.72B | 61.2x | 9.91 | ₹2,436.25 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.2% Upside | Upgrade to Pro+ | |
Ipca Laboratories | BSE | Healthcare | Pharmaceuticals | ₹399.46B | 60.6x | 3.87 | ₹1,573.10 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.1% Upside | Upgrade to Pro+ | |
Ipca Laboratories | NSE | Healthcare | Pharmaceuticals | ₹399.46B | 60.6x | 3.87 | ₹1,574.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8% Upside | Upgrade to Pro+ | |
Ajanta Pharma Ltd-BO | BSE | Healthcare | Pharmaceuticals | ₹366.41B | 42.1x | 1.2 | ₹2,939.65 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.2% Upside | Upgrade to Pro+ | |
Ajanta Pharma Ltd | NSE | Healthcare | Pharmaceuticals | ₹366.41B | 42.1x | 1.2 | ₹2,933.95 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.4% Upside | Upgrade to Pro+ |